Cargando…
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world st...
Ejemplares similares
-
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
por: Santoni, Matteo, et al.
Publicado: (2021) -
Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States
por: Santoni, Matteo, et al.
Publicado: (2021) -
The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications
por: Aurilio, Gaetano, et al.
Publicado: (2019) -
Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer
por: Giulietti, Matteo, et al.
Publicado: (2018) -
Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges
por: Santoni, Matteo, et al.
Publicado: (2019)